← Back to Clinical Trials
Recruiting NCT07228312

NCT07228312 A Study of Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07228312
Status Recruiting
Phase
Sponsor Johnson & Johnson Medical (Shanghai) Ltd.
Condition Intracranial Aneurysm
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2026-01-28
Primary Completion 2028-02-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2026-01-28 with a primary completion date of 2028-02-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to assess how safe choydar flow-directed mesh stent is and how well it works in the treatment of unruptured intracranial aneurysms (a condition in which a bulging blood vessel in the brain can burst and cause bleeding) in a real-world setting.

Eligibility Criteria

Inclusion criteria: Participants meeting all the following inclusion criteria will be included: Preoperative inclusion criteria: * Presence of unruptured aneurysms in the internal carotid artery (from the petrous segment to the distal end) or vertebral artery identified by digital subtraction angiography (DSA), computed tomography angiography (CTA), or magnetic resonance angiography (MRA) prior to surgery, wide-neck (neck width greater than or equal to \[\>=\] 4 millimeters \[mm\] or dome-to-neck ratio less than \[\<\] 2) saccular or fusiform aneurysms, and the parent artery diameter must be \>= 2.0 mm and less than or equal to \[\<=\] 6.0 mm * Participants and/or their authorized representatives understand the purpose of the study, and are willing to voluntarily participate in the study and sign the informed consent form (ICF) * Prior to enrollment, a clinical decision has already been made to use the choydar flow-directed mesh stent * Participants who are willing and able to return for all follow-up visits as required by the study protocol Intraoperative inclusion criteria: \- Presence of unruptured aneurysms in the internal carotid artery (from the petrous segment to the distal end) or vertebral artery identified by DSA during the procedure, wide-neck (neck width \>= 4 mm or dome-to-neck ratio \<2) saccular or fusiform aneurysms, and the parent artery diameter must be \>= 2.0 mm and \<= 6.0 mm Exclusion criteria: Participants meeting any of the following exclusion criteria will be excluded: * Participants with anatomy are unsuitable for flow diverter passage or placement or lesions unsuitable for flow diverter delivery and deployment (for example, the lesion vessel is excessively tortuous or tiny, the flow diverter cannot reach the lesion site, stenosis exists in the target vessel of recurrent aneurysm, or the flow diverter is not completely deployed) * Participants who are allergic to contrast media * Participants who are allergic to nickel-titanium alloy or platinum-tungsten alloy * Participants who are contraindicated for antiplatelet and/or anticoagulant therapy * Participants with active bacterial infections * Participants who are confirmed positive pregnancy (for example, via test or oral communication) according to the site-specific standard of care * Participants who are currently participating in an investigational (drug, device, etc.) clinical study that may confound the study endpoints (excluding observational, natural history, and/or epidemiological studies that do not require interventions)

Contact & Investigator

Central Contact

Yuanyuan Gu

✉ ygu51@its.jnj.com

📞 86 15692105615

Principal Investigator

Johnson & Johnson Medical (Shanghai) Ltd. Clinical Trial

STUDY DIRECTOR

Johnson & Johnson Medical (Shanghai) Ltd.

Frequently Asked Questions

Who can join the NCT07228312 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Intracranial Aneurysm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07228312 currently recruiting?

Yes, NCT07228312 is actively recruiting participants. Contact the research team at ygu51@its.jnj.com for enrollment information.

Where is the NCT07228312 trial being conducted?

This trial is being conducted at Guangzhou, China, Nanjing, China, Zhengzhou, China.

Who is sponsoring the NCT07228312 clinical trial?

NCT07228312 is sponsored by Johnson & Johnson Medical (Shanghai) Ltd.. The principal investigator is Johnson & Johnson Medical (Shanghai) Ltd. Clinical Trial at Johnson & Johnson Medical (Shanghai) Ltd.. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology